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Abstract 
Background: Patients with SARS‑CoV‑2 infection are at higher risk for ventilator‑associated pneumonia (VAP). No 
study has evaluated the relationship between VAP and mortality in this population, or compared this relationship 
between SARS‑CoV‑2 patients and other populations. The main objective of our study was to determine the relation‑
ship between VAP and mortality in SARS‑CoV‑2 patients.
Methods: Planned ancillary analysis of a multicenter retrospective European cohort. VAP was diagnosed using 
clinical, radiological and quantitative microbiological criteria. Univariable and multivariable marginal Cox’s regression 
models, with cause‑specific hazard for duration of mechanical ventilation and ICU stay, were used to compare out‑
comes between study groups. Extubation, and ICU discharge alive were considered as events of interest, and mortal‑
ity as competing event.
Findings: Of 1576 included patients, 568 were SARS‑CoV‑2 pneumonia, 482 influenza pneumonia, and 526 no 
evidence of viral infection at ICU admission. VAP was associated with significantly higher risk for 28‑day mortality in 
SARS‑CoV‑2 (adjusted HR 1.70 (95% CI 1.16–2.47), p = 0.006), and influenza groups (1.75 (1.03–3.02), p = 0.045), but 
not in the no viral infection group (1.07 (0.64–1.78), p = 0.79). VAP was associated with significantly longer duration 
of mechanical ventilation in the SARS‑CoV‑2 group, but not in the influenza or no viral infection groups. VAP was 
associated with significantly longer duration of ICU stay in the 3 study groups. No significant difference was found in 
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Background
Coronavirus disease-19 (COVID-19) pandemic is ongo-
ing, and several million patients have been hospital-
ized in intensive care units (ICUs) worldwide. A large 
percentage of COVID-19 patients admitted to the ICU 
require invasive mechanical ventilation, and are at higher 
risk for ventilator-associated pneumonia (VAP) [1]. In 
the large multicenter European coVAPid study [2], SARS-
CoV-2 infection was associated with higher risk for VAP, 
and ventilator associated tracheobronchitis (VAT), as 
compared to patients with influenza, or no viral infec-
tion at ICU admission. Other recent studies [3–7] con-
firmed these results and reported a high incidence of 
VAP ranging from 44 to 86%. This could be explained by 
the prolonged duration of mechanical ventilation in these 
patients, high rate of acute respiratory distress syndrome 
(ARDS), common use of corticosteroids, and perhaps 
specific factors related to severe acute respiratory syn-
drome Coronavirus 2 (SARS-CoV-2) infection.
Several studies, performed in general ICU populations 
and using different methods, showed higher mortality 
rates, and longer duration of mechanical ventilation and 
ICU stay in VAP patients, as compared with those with 
no VAP [8–13]. To our knowledge, no study to date has 
specifically addressed the effect of VAP on mortality in 
SARS-CoV-2 patients, or the impact of SARS-CoV-2 
infection on the relationship between VAP and mortality. 
Therefore, we conducted this planned ancillary study of 
the coVAPid European multicenter cohort to determine 
the impact of VAP on mortality in SARS-CoV-2 patients. 
We also aimed to determine the impact of SARS-CoV-2 
pneumonia, as compared with influenza pneumonia or 
no viral infection at ICU admission, on the relationship 
between VAP and mortality.
Methods
Study design and population
This study is a planned ancillary analysis of the coVAPid 
cohort study. Briefly, coVAPid was a multicenter retro-
spective observational European cohort study. Eligibility 
criteria included age equal or above 18  years, the need 
for invasive mechanical ventilation for more than 48  h, 
and one of the following criteria at ICU admission: (1) 
SARS-CoV-2 pneumonia, (2) influenza (A or B) pneumo-
nia, or (3) no viral infection.
The Ethics Committee, and Institutional Review Boards 
approved the study protocol (Comité de Protection des 
Personnes Ouest VI; approved by April 14, 2020; regis-
tration number RIPH:20.04.09.60039) as minimal-risk 
research using data collected for routine clinical prac-
tice, and waived the requirement for informed consent. 
The study was registered at ClinicalTrials.gov, number 
NCT04359693.
SARS-CoV-2 infection was confirmed by positive poly-
merase chain reaction (PCR) testing of a nasopharyngeal 
or respiratory secretions samples. Influenza pneumonia 
was diagnosed based on a positive nasopharyngeal or air-
way secretions PCR test.
Definitions
Ventilator‑associated lower respiratory tract infection
The diagnosis of VA-LRTI was based on the presence of 
at least two of the following criteria: body temperature of 
more than 38.5  °C or less than 36.5  °C, leucocyte count 
greater than 12,000 cells per μL or less than 4000 cells per 
μL, and purulent tracheal secretions [14, 15].  Addition-
ally, all episodes of infection needed microbiological con-
firmation, with the isolation in the endotracheal aspirate 
of at least  105 colony-forming units (CFU) per mL, or in 
bronchoalveolar lavage of at least  104 CFU per mL. VAT 
was defined with the above-mentioned criteria with no 
radiographic signs of new pneumonia. VAP was defined 
by the presence of new or progressive infiltrates on chest 
X-ray. Only first episodes of VAT and VAP occurring 
more than 48 h after starting invasive mechanical ventila-
tion were analyzed. All VA-LRTI episodes were prospec-
tively identified, and chest X-rays were reviewed by at 
least two attending physicians. In case of disagreement, 
a third physician was asked to interpret the radiograph. 
Late-onset VAP was defined as VAP diagnosed after 4 
days of invasive mechanical ventilation [15].  Initial anti-
biotic treatment was considered as appropriate when at 
least one antibiotic, matching the in vitro susceptibility of 
the pathogen causing VAP, was given to treat this infec-
tion [16].
heterogeneity of outcomes related to VAP between the 3 groups, suggesting that the impact of VAP on mortality was 
not different between study groups.
Interpretation: VAP was associated with significantly increased 28‑day mortality rate in SARS‑CoV‑2 patients. How‑
ever, SARS‑CoV‑2 pneumonia, as compared to influenza pneumonia or no viral infection, did not significantly modify 
the relationship between VAP and 28‑day mortality.
Clinical trial registration: The study was registered at ClinicalTrials.gov, number NCT04359693.
Keywords: Ventilator‑associated pneumonia, Mortality, COVID‑19
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Outcomes
The primary outcome of this ancillary study was 28-day 
all-cause mortality. Secondary outcomes included dura-
tion of mechanical ventilation, and ICU length of stay 
censored at 28 days.
Statistical analysis
Quantitative variables were expressed as medians (inter-
quartile range) and categorical variables were expressed 
as numbers (percentage). Patient characteristics at ICU 
admission and during ICU stay were described accord-
ing to study disease groups (SARS-CoV-2 pneumonia 
vs. Influenza pneumonia vs. no viral infection) without 
formal statistical comparisons. Patient’s outcomes (over-
all survival, mechanical ventilation duration, length of 
ICU stay) were described according to study disease 
groups using survival analysis approach by estimating the 
cumulative incidence of event of interest (death, extuba-
tion alive and ICU discharge alive) censored at 28-days. 
Cumulative incidence of death was estimated using 
Kaplan–Meier method, cumulative incidence of extuba-
tion alive and ICU discharge alive were estimated using 
Kalbfleisch and Prentice method, considering death as 
competing event [17].
We assessed the effect of SARS-CoV-2 pneumonia 
compared to the two other disease groups on patient’s 
outcomes using a univariable and multivariable marginal 
Cox’s regression models to account clustered (center) 
data, with cause-specific hazard for mechanical ventila-
tion duration and length of ICU stay (considering extuba-
tion alive and ICU discharge alive as event of interest, and 
death as competing event). Pre-specified potential pre-
dictors of patient outcomes (age, gender, SAPS II, Charl-
son score, McCabe classification, shock and ARDS) were 
included as covariates into multivariable models. Hazard 
ratios (HRs) for SARS-CoV-2 pneumonia vs. Influenza 
pneumonia, and HRs for SARS-CoV-2 pneumonia vs. no 
viral infection were derived from Cox’s models as effect 
size. A HR > 1 indicates a decrease in survival, mechani-
cal ventilation duration and length of ICU stay, whereas a 
HR < 1 indicates an increase in survival, mechanical ven-
tilation duration and length of ICU stay.
In each disease group, we assessed the association of 
first episodes of VA-LRTI with patient’s outcomes using 
univariable and multivariable marginal Cox’s regression 
models, with cause-specific hazard for mechanical venti-
lation duration and length of ICU stay and by considering 
the first VA-LRTI occurrence as a time-dependent covar-
iate (3-levels categorical variable: No VA-LRTI, vs. VAT, 
vs. VAP); as well as binary variable: No VA-LRTI vs. VA-
LRTI (VAT or VAP). This model accounted for exposure 
time of VA-LRTI, by comparing at each follow-up time 
point, the current VA-LRTI status of patients who have 
the event to patients who are at risk (without the event of 
interest and without the competing event for mechanical 
ventilation duration and length of ICU stay) [18].
HRs associated with VAT, VAP, and no VA-LRTI were 
derived as effect size using time period without VA-LRTI 
as reference. To assess whether the association between 
VA-LRTI and outcomes differed between the three dis-
ease groups, a heterogeneity test was performed [19], 
comparing the HRs for VA-LRTI (VAP, VAT, VAT + VAP 
combined) between study groups.
To avoid case-deletion in multivariate analyses due 
to presence of missing data in covariates, multivariable 
Cox’s models were performed after handling missing 
data on covariates by using multiple imputation proce-
dure [20]. This imputation was performed using regres-
sion-switching approach (chained equations with m = 20 
obtained) under the missing at random assumption using 
all baseline characteristics (see Table  1), disease group 
and outcomes (event status and log of event time), with 
a predictive mean matching method for quantitative 
variables and logistic regression model (binary, ordi-
nal or multinomial) for categorical variables. Estimates 
obtained in the different imputed data sets were com-
bined using Rubin’s rules [21].
Statistical testing was performed at the two-tailed α 
level of 0.05. Data were analyzed using the SAS software 
package, release 9.4 (SAS Institute, Cary, NC).
Results
Patient characteristics
In total, 1576 patients were included from March 2016 
through May 2020 (568 in SARS-CoV2, 482 in influ-
enza, and 526 in no viral infection groups). 399 (25.3%) 
VAP, and 167 (10.6%) VAT first episodes were diagnosed 
in study patients. 28-day mortality was 28.8% (164 of 
568 patients), 22% (125 of 482 patients), and 32.9% (173 
of 526 patients) in SARS-CoV-2, influenza, and no viral 
infection groups, respectively. Older age, higher SAPS 
II and SOFA score, comorbidities, septic shock, cardiac 
arrest, and acute kidney injury rates at ICU admission 
were more common in non-survivors, as compared to 
survivors in the 3 study groups. During ICU stay, per-
centage of patients who received corticosteroids, prone 
positioning, and ECMO was higher in non-survivors 
as compared to survivors. The characteristics of study 
patients are presented in Tables 1, and 2.
The cumulative incidence of 28-day mortality, extuba-
tion alive, and ICU discharge alive, according to study 
groups, are presented in Additional file 1: Fig. 1. SARS-
CoV-2 infection was associated with significantly longer 
duration of mechanical ventilation, as compared to influ-
enza and no viral infection groups (Fig. 1). SARS-CoV-2 
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Table 1 Patient characteristics at ICU admission according to disease group, and 28‑day mortality
Values are as no./No. (%) or median (interquartile range)
McCabe classification of comorbidities and likelihood of survival, likely to survive > 5 years, 1–5 years, < 1 year; Chronic renal failure, KDOQI CKD classification stage 4 or 
5 (creatinine clearance < 30 ml/mn); Chronic heart failure, NYHA class III or IV; Heart disease, ischemic heart disease or atrial fibrillation; Cirrhosis, Child–Pugh score B or 
C; Immunosuppression if haematological malignancy, allogenic stem cell transplant, organ transplant, HIV or immunosuppressive drugs; More than one cause for ICU 
admission is possible
a 1 missing value in influenza group; b 160 missing values (SARS-CoV-2, n = 32; influenza, n = 68; controls, n = 60); c 87 missing values (SARS-CoV-2, n = 43; influenza, 
n = 21; controls, n = 21); d 27 missing values (SARS-CoV-2, n = 21; influenza, n = 4; controls, n = 2); e 50 missing values (SARS-CoV-2, n = 19; influenza, n = 11; controls, 
n = 20)
SARS-CoV-2 pneumonia Influenza pneumonia No viral infection
Alive (n = 402) Dead (n = 166) Alive (n = 350) Dead (n = 132) Alive (n = 344) Dead (n = 182)
Age,  yearsa 62 (53–70) 70 (62–78) 61 (52–70) 65 (54–72) 63 (52–72) 70 (60–76)
Men 281/402 (69.9) 126/166 (75.9) 219/350 (62.6) 79/131 (60.3) 239/342 (69.9) 114/182 (62.6)
Body mass index, kg/m2 b 28.7 (25.5–33.6) 29.1 (26.0–33.0) 27.5 (23.1–32.3) 27.6 (23.5–31.7) 26.3 (22.7–29.8) 26.9 (23.2–33.3)
Severity scores
SAPS  IIc 38 (31–51) 48 (38–61) 48 (37–60) 58 (45–72) 51 (39–63) 63 (51–73)
SOFA  scored 6 (3–8) 7 (4–10) 8 (5–10) 10 (7–13) 8 (5–11) 9 (7–12)
Comorbidity scores
MacCabe classification
 Non‑fatal 347/382 (90.8) 128/161 (79.5) 249/332 (75.0) 75/124 (60.5) 216/318 (67.9) 99/171 (57.9)
 Fatal < 5 years 33/382 (8.6) 29/161 (18.0) 78/332 (23.5) 36/124 (29.0) 90/318 (28.3) 47/171 (27.5)
 Fatal < 1 year 2/382 (0.5) 4/161 (2.5) 5/332 (1.5) 13/124 (10.5) 12/318 (3.8) 25/171 (14.6)
Charlson Comorbidity  Indexe 2 (1–3) 4 (2–5) 3 (2–5) 4 (2–6) 3 (2–5) 5 (3–6)
Chronic diseases
 Diabetes mellitus 113/399 (28.3) 55/166 (33.1) 72/344 (20.9) 32/130 (24.6) 82/338 (24.3) 50/181 (27.6)
 Chronic renal failure 11/395 (2.8) 22/164 (13.4) 25/346 (7.2) 14/129 (10.9) 22/339 (6.5) 23/182 (12.6)
 Cardiovascular disease 59/396 (14.9) 44/164 (26.8) 80/346 (23.1) 37/130 (28.5) 72/337 (21.4) 62/181 (34.3)
 Chronic heart failure 12/394 (3.0) 9/164 (5.5) 19/345 (5.5) 18/130 (13.8) 24/336 (7.1) 26/182 (14.3)
 COPD 26/396 (6.6) 11/164 (6.7) 96/344 (27.9) 33/131 (25.2) 63/339 (18.6) 35/182 (19.2)
 Chronic respiratory failure 12/394 (3.0) 8/164 (4.9) 56/344 (16.3) 11/131 (8.4) 28/336 (8.3) 21/182 (11.5)
 Cirrhosis 6/395 (1.5) 2/164 (1.2) 10/345 (2.9) 6/130 (4.6) 18/335 (5.4) 18/181 (9.9)
 Immunosuppression 29/395 (7.3) 23/164 (14.0) 61/348 (17.5) 46/131 (35.1) 71/340 (20.9) 46/180 (25.6)
 Active smoking 20/396 (5.1) 9/164 (5.5) 122/346 (35.3) 27/130 (20.8) 102/337 (30.3) 35 /182 (19.2)
 Alcohol abuse 29/394 (7.4) 5/164 (3.0) 65/345 (18.8) 20/130 (15.4) 89/337 (26.4) 43/182 (23.6)
Location before ICU admission
 Home 187/402 (46.5) 84/166 (50.6) 212/349 (60.7) 63/132 (47.7) 180/344 (52.3) 85/182 (46.7)
 Hospital ward 154/402 (38.3) 61/166 (36.7) 104/349 (29.8) 53/132 (40.2) 147/344 (42.7) 83/182 (45.6)
 Another ICU 61/402 (15.2) 21/166 (12.7) 33/349 (9.5) 16/132 (12.1) 17/344 (4.9) 14/182 (7.7)
Admission category
 Medical 401/402 (99.8) 166/166 (100.0) 348/350 (99.4) 132/132 (100.0) 302/344 (87.8) 165/182 (90.7)
 Surgical 0/402 (0.0) 0/166 (0.0) 0/350 (0.0) 0/132 (0.0) 11/344 (3.2) 6/182 (3.3)
 Trauma 1/402 (0.2) 0/166 (0.0) 2/350 (0.6) 0/132 (0.0) 31/344 (9.0) 11/182 (6.0)
Recent hospitalization (< 3 months) 26/401 (6.5) 18/165 (10.9) 41/348 (11.8) 31/131 (23.7) 90/342 (26.3) 58/182 (31.9)
Recent antibiotic treatment (< 3 months) 50/402 (12.4) 24/165 (14.5) 56/347 (16.1) 39/130 (30.0) 56/342 (16.4) 47/182 (25.8)
Causes for ICU admission
 Shock 58/394 (14.7) 44/163 (27.0) 144/343 (42.0) 66/127 (52.0) 147/336 (43.8) 97/179 (54.2)
 Acute respiratory failure 371/401 (92.5) 150/166 (90.4) 316/349 (90.5) 117/131 (89.3) 196/334 (58.7) 83/179 (46.4)
 ARDS 271/398 (68.1) 115/165 (69.7) 157/342 (45.9) 63/127 (49.6) 44/330 (13.3) 28/179 (15.6)
 Neurological failure 13/385 (3.4) 13/163 (8.0) 51/339 (15.0) 18/126 (14.3) 128/331 (38.7) 63/178 (35.4)
 Cardiac arrest 1/384 (0.3) 2/163 (1.2) 14/338 (4.1) 11/127 (8.7) 40/329 (12.2) 44/179 (24.6)
 Acute kidney injury 48/385 (12.5) 48/163 (29.4) 84/337 (24.9) 49/124 (39.5) 87/327 (26.6) 49/178 (27.5)
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Table 2 Patient characteristics during ICU stay according to disease groups and 28‑day mortality
Vales are no./No. (%) or median (interquartile range)
ECMO, Extracorporeal Membrane Oxygenation; ICU, Intensive Care Unit; MV, Mechanical Ventilation
a 11 missing values (SARS-CoV-2, n = 4; influenza, n = 4; controls, n = 3); b16missing values (SARS-CoV-2, n = 7; influenza, n = 3; controls, n = 6)
SARS-CoV-2 pneumonia Influenza pneumonia No viral infection
Alive (n = 402) Dead (n = 166) Alive (n = 350) Dead (n = 132) Alive (n = 344) Dead (n = 182)
Antiviral treatment 226/401 (56.4) 96/165 (58.2) 319/349 (91.4) 118/132 (89.4) 19/343 (5.5) 5/180 (2.8)
 Oseltamivir 30/399 (7.5) 14/164 (8.5) 314/344 (91.3) 116/131 (88.5) 18/342 (5.3) 4/179 (2.2)
 Remdesivir 21/399 (5.3) 6/164 (3.7) 0/344 (0.0) 0/131 (0.0) 0/342 (0.0) 0/179 (0.0)
 Lopinavir‑Ritonavir 96/399 (24.1) 51/164 (31.1) 0/344 (0.0) 0/131 (0.0) 0/342 (0.0) 0/179 (0.0)
 Lopinavir‑Ritonavir + interferon 12/399 (3.0) 9/164 (5.5) 0/344 (0.0) 0/131 (0.0) 0/342 (0.0) 0/179 (0.0)
 Hydroxychloroquine 134/399 (33.6) 39/164 (23.8) 0/344 (0.0) 1/131 (0.8) 0/342 (0.0) 0/179 (0.0)
Corticosteroids 131/380 (34.5) 71/162 (43.8) 124/345 (35.9) 58/130 (44.6) 97/343 (28.3) 64/182 (35.2)
 Hydrocortisone 27/377 (7.2) 32/160 (20.0) 64/343 (18.7) 43/130 (33.1) 39/340 (11.5) 41/180 (22.8)
 Dexamethasone 32/377 (8.5) 16/160 (10.0) 1/343 (0.3) 0/130 (0.0) 6/340 (1.8) 4/180 (2.2)
 Methylprednisolone 70/377 (18.6) 21/160 (13.1) 58/343 (16.9) 15/130 (11.5) 51/340 (15.0) 17/180 (9.4)
 Highest daily dose,  mga 100 (67–133) 71 (50–133) 75 (50–100) 50 (50–100) 63 (50–100) 50 (50–75)
 Duration,  daysb 6 (4–9) 6 (4–8) 5 (3–9) 6 (3–9) 4 (2–7) 4 (3–8)
Antibiotic treatment 363/378 (96.0) 143/153 (93.5) 309/330 (93.6) 125/128 (97.7) 268/323 (83.0) 147/173 (85.0)
 Duration, days 7 (5–9) 7 (4–10) 7 (5–11) 7 (4–9) 7 (4–9) 6 (4–9)
Prone positioning 263/401 (65.6) 120/166 (72.3) 96/349 (27.5) 55/132 (41.7) 33/340 (9.7) 30/182 (16.5)
ECMO 39/402 (9.7) 22/165 (13.3) 38/349 (10.9) 22/131 (16.8) 2/341 (0.6) 3/182 (1.6)
Fig. 1 Unadjusted and Adjusted hazard ratios for 28‑day mortality, extubation alive and ICU discharge alive, associated with SARS‑CoV‑2 
pneumonia, versus influenza pneumonia and no viral infection groups. HRs were calculated using cause‑specific proportional hazard models, by 
considering mortality as competing event for MV duration, and length of ICU stay. Adjusted HRs were calculated, including age, gender, simplified 
acute physiology score II, Charlson score, MacCabe classification, shock, and acute respiratory distress syndrome as pre‑specified covariates in Cox’s 
models (after handling missing values by multiple imputation). A HR > 1 indicates a decrease in survival duration (i.e. an increased risk for mortality), 
MV duration (i.e. an increased risk for extubation alive) and ICU length of stay (i.e. an increased risk for discharge alive) and a HR < 1 indicates an 
increase in survival duration (i.e. a decreased risk for mortality), MV duration (i.e. a decreased risk for extubation alive) and ICU length of stay (i.e. a 
decreased risk for discharge alive). Note that the event of interest for survival is a pejorative event (death) whereas for MV duration and ICU length 
of stay, the event of interest is a positive event (extubation or discharge alive). Consequently, the detrimental effect of SARS‑CoV‑2 pneumonia 
(vs influenza pneumonia and no viral infection groups) was associated with a HR > 1 for overall survival but was associated with a HR < 1 for MV 
duration and ICU length of stay. HR, hazard ratio; ICU, intensive care unit; MV, mechanical ventilation
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infection was also associated with significantly higher 
risk for mortality, as compared to influenza group (Fig. 1).
Characteristics of patients with ventilator-associated 
pneumonia
Antimicrobial treatment was prescribed to 191 of 205 
(93.2%), 98 of 105 (93.3), and 82 of 87 (94.3) patients 
with VAP in SARS-CoV-2, influenza, and no viral infec-
tion groups; respectively. Initial antibiotic treatment was 
appropriate in 145 of 200 (72.5%), 69 of 102 (67.7%), and 
54 of 87 (62.1%) VAP patients in SARS-CoV-2, influenza, 
and no viral infection group; respectively. Median (inter-
quartile range) time from starting invasive mechani-
cal ventilation to VAP occurrence was 9 (6, 13) days in 
SARS-CoV-2, 9 (5, 13) days in influenza, and 7 (4, 12) 
days in no viral infection groups. Percentage of patients 
with late-onset VAP was 82.4% (169 of 200 patients), 
73.8% (79 of 102 patients), and 65.5% (57 of 87 patients) 
in SARS-CoV-2, influenza, and no viral infection group; 
respectively. Pseudomonas aeruginosa, Enterobacter spp., 
and Klebsiella spp. were the most frequently identified 
microorganisms (Table  3). Percentage of VAP patients 
with MDR was lower in SARS-CoV-2 patients as com-
pared to the two other groups, as well as percentage of 
patients with late-onset VAP related to MDR (35 of 167 
patients (21%), 27 of 78 patients (34.6%), and 20 of 57 
patients (35.1%), in SARS-CoV-2, influenza, and no viral 
infection groups; respectively).
Primary and secondary study outcomes
VAP was associated with significantly higher risk for 
28-day mortality in SARS-CoV-2, and influenza groups, 
but not in no viral infection group (Fig.  2A). However, 
the heterogeneity test showed no significant difference in 
the strength of association between VAP and mortality 
across the 3 study groups.
VAP was associated with significantly longer duration 
of mechanical ventilation in the SARS-CoV-2 group, but 
not in influenza or no viral infection groups. The hetero-
geneity test showed no significant difference between 
the 3 groups regarding the association between VAP and 
duration of mechanical ventilation (Fig. 2B).
Table 3 Microorganisms responsible for ventilator‑associated pneumonia
Data are presented as N (%)
* Missing data: 2, 2 in SARS-CoV-2 and Influenza groups; respectively
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus




 MSSA 20 (9.8) 5 (4.7) 8 (9.2)
 MRSA 6 (2.9) 4 (3.7) 2 (2.3)
 Enterococcus spp. 7 (3.4) 2 (1.9) 2 (2.3)
 Streptococcus pneumoniae 7 (3.4) 1 (1) 2 (2.3)
 Streptococcus spp. 1 (0.5) 0 (0) 0 (0)
 Other 0 (0) 2 (1.9) 3 (3.5)
Gram‑negative bacilli
 Pseudomonas aeruginosa 51 (24.9) 26 (24.3) 15 (17.2)
 Enterobacter spp. 37 (18) 15 (14) 12 (13.8)
 Klebsiella spp. 26 (12.7) 17 (15.9) 12 (13.8)
 Escherichia coli 19 (9.2) 8 (7.5) 5 (5.7)
 Acinetobacter baumannii 9 (4.4) 16 (15) 10 (11.5)
 Stenotrophomonas maltophilia 4 (2) 2 (1.9) 4 (4.6)
 Serratia marcescens 9 (4.4) 4 (3.7) 1 (1.1)
 Citrobacter freundii 6 (2.9) 1 (1) 1 (1.1)
 Citrobacter spp. 5 (2.4) 3 (2.8) 3 (3.5)
 Proteus mirabilis 5 (2.4) 1 (1) 2 (2.3)
 Haemophilus influenza 3 (1.5) 5 (4.7) 5 (5.7)
 Morganella morganii 2 (1) 3 (2.8) 0 (0)
 Other 26 (12.7) 8 (7.5) 5 (5.7)
Polymicrobial 24 (11.7) 8 (7.5) 6 (6.9)
Multidrug‑resistant isolates* 42 (20.7) 42 (40) 27 (31)
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VAP was associated with significantly longer duration 
of ICU stay in all study groups. The heterogeneity test 
showed no significant difference between the 3 groups 
regarding the association between VAP and ICU length 
of stay (Fig. 2C).
VAT was not significantly associated with increased 
risk for mortality, or longer duration of mechanical ven-
tilation in the 3 study groups. VAT was associated with 
significantly longer ICU stay in no viral infection group, 
but not in the two other groups. The heterogeneity test 
was significant between the 3 groups regarding duration 
of ICU stay (Fig. 2a–c).
Descriptive characteristics and outcomes of patients 
with, or without, VA-LRTI are presented in Additional 
file 1: Tables 1, and 2. The association between VA-LRTI 




The main results of our study are that VAP is associated 
with increased 28-day mortality rate and longer dura-
tion of mechanical ventilation and ICU length of stay in 
SARS-CoV-2 patients. SARS-CoV-2 infection, compared 
with influenza or no viral infection, has no significant 
impact on the relationship between VAP and 28-day 
mortality, neither on the relationship between VAP and 
duration of mechanical ventilation, or ICU length of stay.
Relationship between VAP and mortality in SARS-CoV-2 
patients
Few data are available on mortality rate in SARS-CoV-2 
patients with VAP. Although several recent studies evalu-
ated the incidence of VAP in these patients, only one 
study performed in ARDS patients requiring ECMO 
[6], reported on mortality rate (30%) in this population. 
However, this study was performed in a single center, the 
number of patients with SARS-CoV-2 infection was small 
(n = 50), and no comparison was performed with mortal-
ity rate in SARS-CoV-2 patients with no VAP.
Previous studies, performed in general ICU popu-
lations, showed an increased mortality rate in VAP 
patients [22–25]. A large meta-analysis was performed 
on individual data from 6284 patients included in rand-
omized controlled trials of VAP prevention [8]. The over-
all attributable mortality of VAP was 13%, with higher 
rates for surgical patients and patients with a mid-range 
severity score at admission. Attributable mortality was 
mainly caused by prolonged exposure to the risk of dying 
due to increased length of ICU stay. However, other 
studies suggested that mortality attributable to VAP was 
small [26, 27].
Impact of SARS-CoV-2 infection on the relationship 
between VAP and mortality
Multidrug resistant bacteria (MDR) bacteria and inap-
propriate initial antibiotic treatment are well-known risk 
factors for mortality in VAP patients [28, 29]. Although 
the incidence of MDR, and inappropriate initial antibi-
otic treatment was lower in COVID-19 patients, as com-
pared to the two other groups, the relationship between 
VAP and mortality was only significant in COVID-19 
patients. This suggests that SARS-CoV-2 infection and 
specific pulmonary lesions might play a role in the sever-
ity and outcome of VAP in this population. Neverthe-
less, the absence of significant heterogeneity between the 
three groups suggests that SARS-CoV-2 infection has no 
significant impact on the relationship between VAP and 
mortality. At least three explanations could be provided 
for this result. First, potential confounders might have 
influenced our results. However, careful adjustment was 
performed on SAPS II, age, gender, comorbidities, sep-
tic shock, and ARDS, based on the results of prior stud-
ies [13, 30]. Second, the number of patients with VAP 
was relatively small in the no viral infection group, and 
the study might have been underpowered to detect a 
significant effect. Third, SARS-CoV-2 infection could 
be associated with similar impact on the relationship 
between VAP and mortality. Previous studies suggested 
that COVID-19 patients have similar outcomes as other 
patients with similar type of acute illness. For example, 
a recent study reported a 90-day mortality rate of 37% 
in COVID-19 ARDS [1], which is in line with previous 
results in non-COVID ARDS [31].
Fig. 2 Association between ventilator‑associated lower respiratory tract infections and outcomes. a 28‑Day mortality. b Duration of mechanical 
ventilation. c Length of ICU stay. HRs were calculated using cause‑specific proportional hazard models, considering the first VA‑LRTI as a time 
dependent 3‑levels categorical variable (No VA‑LRTI vs. VAT vs. VAP). Adjusted HRs were calculated including age, gender, simplified acute 
physiology score II, Charlson score, MacCabe classification, shock, and acute respiratory distress syndrome as pre‑specified covariables in Cox’s 
model. Since the event of interest for 28‑Day mortality is a pejorative event (death), whereas for MV duration and ICU length of stay, the event of 
interest is a positive event (extubation or discharge alive), the detrimental effect of SARS‑CoV‑2 pneumonia (vs influenza pneumonia and no viral 
infection groups) was associated with a HR > 1 for 28‑Day mortality, with a HR < 1 for MV duration and ICU length of stay. HR, hazard ratio; ICU, 
intensive care unit; MV, mechanical ventilation; VA‑LRTI, ventilator‑associated respiratory tract infection; VAP, ventilator‑associated pneumonia; VAT, 
ventilator‑associated tracheobronchitis
(See figure on next page.)
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Strengths and limitations
To our knowledge, our study is the first to evaluate the 
relationship between VAP and mortality in SARS-CoV-2 
patients. Strengths of this study are the large number of 
included patients, the multicenter design, and the two con-
trol groups including patients with influenza pneumonia 
or no viral infection. In addition, we carefully adjusted for 
potential confounders, using competing risk analyses, and 
Kalbfleisch and Prentice methods. Cox’s model took into 
account the immortal time bias, by considering VAP as 
time-dependent covariable [32]. The discrepancy between 
the lower mortality rate in SARS-CoV-2 patients with VAP, 
as compared with those with no VA-LRTI (Additional 
file 1: Table 2), and the adjusted hazard ratio showing an 
increased risk for mortality in the former than in the latter 
group (Fig. 2 A) is explained by the immortal time bias in 
the calculation of actual mortality rate.
Some limitations of this study should be acknowledged. 
First, coVAPid cohort was retrospective. However, VAP 
was prospectively identified in all centers. Further, the pres-
ence of new infiltrate on chest X-ray was evaluated by at 
least two physicians. Second, the study was performed in 
Europe, and the results may not be generalized to other 
world regions. Third, number of patients was relatively 
small in some subgroups with VAP or VAT, and our study 
might have been underpowered to detect differences 
regarding some secondary outcomes. Fourth, in spite of 
careful adjustment, our analysis might have missed some 
residual confounders. Fifth, the interpretation of chest-x 
ray is a difficult task in patients with pneumonia or ARDS. 
In spite of evaluation of chest-X ray by at least two phy-
sicians to confirm the presence of new infiltrate, some 
patients with VAP could have been misclassified in the 
VAT group. Further, some patients with VAT (12.6%) devel-
oped subsequent VAP. However, we repeated the analysis 
on the relationship between VAP and mortality, includ-
ing VAT patients and the results did not differ (Additional 
file 1: Fig. 2). Sixth, no information was collected on timing 
of appropriate initial antibiotic treatment. Finally, patients 
were only followed-up until day 28. Therefore, outcomes at 
day 60, or day 90 could not be evaluated.
Conclusions
To conclude, our results suggest that VAP is associated 
with increased 28-day mortality rate and longer dura-
tion of mechanical ventilation and ICU length of stay in 
SARS-CoV-2 patients. However, SARS-CoV-2 infection, 
compared with influenza or no viral infection, has no 
significant impact on the relationship between VAP and 
28-day mortality, or  on the relationship between VAP and 
duration of mechanical ventilation, and   ICU length of 
stay. Further studies are needed to confirm our findings.
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